The 18 most recent market catalysts affecting $CNC, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 16, 2026
Corporate Catalyst
Neutral
Impact 75
Centene Reaffirms FY2026 GAAP EPS expected to be more than $3.11 vs $2.47 Est
Centene (CNC) filed an 8-K to reaffirm its fiscal year 2026 GAAP EPS guidance, stating it expects earnings to be more than $3.11. This is a significant disclosure because it is sub…
Sep 16, 2026
Corporate Catalyst
Neutral
Impact 65
Centene Reaffirms FY26 Adjusted Diluted EPS Guidance Of Greater Than $4.80
Centene's 8-K filing indicates that management will reaffirm its full-year 2026 GAAP diluted EPS guidance of greater than $3.11 and adjusted diluted EPS guidance of greater than $4…
Aug 17, 2026
Corporate Catalyst
Neutral
Impact 65
Centene's CFO Drew Asher To Step Down in December 2026 and Retire From Centene By End Of 2027; Chris Neczypor To Join As EVP abd CFO From January 1, 2027
The departure of a CFO, especially one with a long tenure, is always a notable event for a company. While the extended transition period for Drew Asher mitigates immediate shock, i…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 55
JP Morgan Maintains Neutral on Centene, Raises Price Target to $67
JP Morgan analyst John Stansel has updated his outlook on Centene (CNC) by raising the price target from $60 to $67, while keeping the 'Neutral' rating unchanged. This indicates th…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 55
Bernstein Maintains Outperform on Centene, Raises Price Target to $79
Bernstein analyst Lance Wilkes has raised the price target for Centene (CNC) from $68 to $79 while maintaining an Outperform rating. This action signals increased confidence from a…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 55
Barclays Maintains Overweight on Centene, Raises Price Target to $80
Barclays analyst Andrew Mok maintained an 'Overweight' rating on Centene and raised the price target from $75 to $80. This action signals continued confidence in Centene's performa…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 55
Baird Maintains Neutral on Centene, Raises Price Target to $66
Baird analyst Michael Ha reiterated a 'Neutral' rating on Centene (CNC) but raised the price target from $46 to $66. This substantial increase in the price target, despite the unch…
Jul 28, 2026
Corporate Catalyst
Bullish
Impact 85
Centene Finds Profit Growth Even as Medicaid Membership Softens
Centene's Q2 2026 results significantly exceeded analyst expectations for both earnings and revenue, prompting the company to raise its full-year guidance. This strong performance …
Jul 28, 2026
Corporate Catalyst
Bearish
Impact 85
Centene shares are trading lower after the company reported Q2 financial results. The CEO said the company is expecting a lower year-end membership.
Centene's Q2 earnings report, particularly the CEO's guidance for lower year-end membership, is a significant negative catalyst. This directly impacts the company's revenue project…
Jul 28, 2026
Corporate Catalyst
Bearish
Impact 85
Centene CEO Says Co Is Expecting Lower Year-End Membership Than Its Previous Outlook Through The Back Half Of The Year
Centene's CEO's statement about expecting lower year-end membership than previously anticipated is a significant corporate catalyst. This directly impacts the company's revenue pro…
Jul 28, 2026
Corporate Catalyst
Bullish
Impact 85
Centene FY2026 Adj EPS expected to be more than $4.80 vs $3.52 Est; Raises FY2026 Sales Guidance from $187.500B-$191.500B to $193.500B-$197.500B vs $191.020B Est
Centene (CNC) announced a substantial upward revision to its fiscal year 2026 financial guidance. The company now expects adjusted EPS to be more than $4.80, significantly higher t…
Jul 28, 2026
Corporate Catalyst
Neutral
Impact 75
Centene FY2026 GAAP EPS expected to be more than $3.11 vs $2.47 Est
Centene's 8-K filing reveals a substantial increase in its projected GAAP EPS for fiscal year 2026, moving from an estimated $2.47 to 'more than $3.11'. This represents a significa…
Jul 23, 2026
Corporate Catalyst
Bearish
Impact 75
Centene shares are trading lower amid possible sympathy with peer Molina Healthcare after the company reported Q2 financial results.
This headline indicates a 'sympathy trade' where one company's negative performance (Molina Healthcare) is impacting a peer (Centene) due to perceived industry-wide implications or…
Jul 22, 2026
Corporate Catalyst
Bearish
Impact 75
Centene shares are trading lower amid possible sympathy with peer Molina Healthcare after the company reported Q2 financial results.
This headline indicates a 'sympathy trade' where one company's negative news impacts a peer, even without direct news for the latter. Molina Healthcare's Q2 results likely containe…
Jul 16, 2026
Corporate Catalyst
Neutral
Impact 75
Medicaid's New Twice-A-Year Eligibility Check Starts In December: How To Keep Your Coverage And Which Stocks Feel It
A new federal budget law, effective December 2026, will require Medicaid expansion enrollees to undergo eligibility checks every six months, rather than annually. This administrati…
Jul 14, 2026
Corporate Catalyst
Bullish
Impact 55
TD Cowen Maintains Hold on Centene, Raises Price Target to $65
TD Cowen analyst Ryan Langston maintained a 'Hold' rating on Centene (CNC) but significantly raised the price target from $47 to $65. This action signals an increased confidence in…
Jul 14, 2026
Corporate Catalyst
Bullish
Impact 55
Truist Securities Maintains Buy on Centene, Raises Price Target to $78
Truist Securities analyst David Macdonald has updated his outlook on Centene, raising the price target to $78 from $71 while maintaining a 'Buy' rating. This action signals increas…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 55
Wells Fargo Maintains Equal-Weight on Centene, Raises Price Target to $69
Wells Fargo analyst Stephen Baxter maintained an 'Equal-Weight' rating on Centene (CNC) but significantly raised the price target from $56 to $69. This indicates that while the ana…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.